NASDAQ:GERN
Geron Corporation Stock News
$3.73
-0.200 (-5.09%)
At Close: May 06, 2024
Geron (GERN) Q2 2022 Earnings Call Transcript
03:00am, Friday, 12'th Aug 2022 The Motley Fool
GERN earnings call for the period ending June 30, 2022.
Geron Corporation's (GERN) CEO Dr. John Scarlett on Q2 2022 Results - Earnings Call Transcript
08:27pm, Thursday, 11'th Aug 2022
Geron Corporation (NASDAQ:GERN ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Aron Feingold - Vice President, Investor Relations and Corporate Communications Dr. Jo
Karuna (KRTX) Stock Skyrockets 98.7% in a Month: Here's Why
05:30pm, Thursday, 11'th Aug 2022 Zacks Investment Research
Karuna Therapeutics (KRTX) is progressing well with its pipeline development. KRTX's lead candidate meets late-stage study goals as a potential treatment for adults with schizophrenia.
Allogene (ALLO) Q1 Earnings Beat, Pipeline Progressing Well
06:54pm, Wednesday, 10'th Aug 2022 Zacks Investment Research
Allogene's (ALLO) second-quarter earnings beat estimates. ALLO is on track to initiate a pivotal phase II study on ALLO-501A in large B cell lymphoma in the coming weeks.
Perrigo's (PRGO) Q2 Earnings Misses by a Cent, Sales Beat
04:14pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Perrigo (PRGO) delivers mixed second-quarter 2022 results. Higher demand for cough/cold products continues during the reported quarter. Unfavorable currency movements hurt sales and earnings.
Karuna (KRTX) Lags on Q2 Earnings, Up 71% on Schizophrenia Data
04:03pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Though Karuna's (KRTX) earnings miss estimates, KRTX's lead candidate meets late-stage study goals as a potential treatment for adults with schizophrenia.
Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates
09:35pm, Monday, 08'th Aug 2022 Zacks Investment Research
Acadia (ACAD) delivered earnings and revenue surprises of 16% and 2.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Immunovant (IMVT) Loss Narrows in Q1, Focus on Batoclimab
01:34pm, Monday, 08'th Aug 2022 Zacks Investment Research
Immunovant's (IMVT) earnings beat estimates in the fiscal first quarter ended on Jun 30, 2022. The company is evaluating batoclimab in a pivotal study for treating myasthenia gravis.
All You Need to Know About Geron (GERN) Rating Upgrade to Strong Buy
04:00pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Geron (GERN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
All You Need to Know About Geron (GERN) Rating Upgrade to Strong Buy
01:32pm, Thursday, 04'th Aug 2022
Geron (GERN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
7 Best Penny Stocks Under $3 to Buy in July
10:18am, Wednesday, 13'th Jul 2022
If you think the volatility in the broader indices isn't enough excitement, here are the best penny stocks to consider under $3. The post 7 Best Penny Stocks Under $3 to Buy in July appeared first on
VERU's Shares Jump on Successful COVID-19 Study Results
03:44pm, Friday, 08'th Jul 2022 Zacks Investment Research
VERU gains on the success of its late stage study evaluating the efficacy and safety of oral sabizabulin 9 mg for COVID-19.
Radius (RDUS) Randomizes Patient in Prader-Willi Syndrome Study
03:40pm, Friday, 08'th Jul 2022 Zacks Investment Research
Radius (RDUS) randomizes the first patient in the SCOUT-015 study of pipeline candidate, RAD011, for Prader-Willi Syndrome.
VERU's Shares Jump on Successful COVID-19 Study Results
01:13pm, Friday, 08'th Jul 2022
VERU gains on the success of its late stage study evaluating the efficacy and safety of oral sabizabulin 9 mg for COVID-19.
Exelixis (EXEL) Collaborates With Ryvu for Cancer Therapies
03:30pm, Thursday, 07'th Jul 2022 Zacks Investment Research
Exelixis (EXEL) teams up with Ryvu Therapeutics to develop novel STING agonist-based targeted cancer therapies.
